Computer Aided Drug Design: GPCRs and Proteases

Madala, Praveen Kumar. (2008). Computer Aided Drug Design: GPCRs and Proteases PhD Thesis, Institute for Molecular Bioscience, The University of Queensland.

       
Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
n40453518_phd_totalthesis.pdf n40453518_phd_totalthesis.pdf application/pdf 52.11MB 3
Author Madala, Praveen Kumar.
Thesis Title Computer Aided Drug Design: GPCRs and Proteases
School, Centre or Institute Institute for Molecular Bioscience
Institution The University of Queensland
Publication date 2008-01-04
Thesis type PhD Thesis
Supervisor Fairlie, David
Stoermer, Martin J.
Language eng
Subjects 06 Biological Sciences
Formatted abstract
Structure-based drug design is one of the more successful approaches used in medicinal chemistry to design and develop new drugs. One approach in structure-based drug design is to use high performance computers for analysing proteins and designing new lead molecules. Among different computer-aided drug design approaches are comparative homology modelling of proteins and different ligand docking techniques, which are reviewed in Chapter 1. Some of these techniques have been applied to compounds that bind to G-protein coupled receptors and aspartic proteases. In Chapter 1, I have therefore discussed the importance of GPCRs and the use of homology modelling techniques, as well as the importance of aspartic proteases and their inhibitors.
Chapter 2 describes the putative binding of three different antagonists to the human complement-5 receptor (hC5aR), which is a GPCR on the surface of immune cells like neutrophils and macrophages. After developing a homology model structure of hC5aR, peptide-30 (N-methyl)-FKP(D-Cha)Wr, cyclic peptide-32 (AcF-[OP(D-Cha)WR]) and nonpeptide-33 (W54011) were docked into the receptor and putative binding sites were tested by mutations in the receptor. By linking the results of modelling with the effects of single receptor mutations on ligand affinity/antagonism, some insights have been provided for the binding sites on C5aR of these three antagonists.
Chapter 3 first develops a protocol for docking known ligands in one GPCR (NK2) to identify the putative receptor-binding location, and then validating the protocol using literature data for effects of site directed mutagenesis on ligand binding to the receptor. The optimised protocol was then applied to 16 different GPCRs, docking known ligands to identify putative binding site on each GPCR, and validating the putative ligand binding site using literature data for effects of site directed receptor mutations on ligand affinity/activity. The conclusion is that there is a common ligand binding site for all 17 different peptide activated GPCRs. The significance of this conclusion is discussed in relation to GPCRs and drug design.
Chapter 4 describes two modelling projects involving aspartic proteases. One project uses crystal structures of HIV-1 protease and its small molecule inhibitors to predict their potential binding to aspartic proteases of Plasmodium falciparum (human malarial parasite)

Keyword Drugs -- Design -- Data processing
Computer-aided design
Membrane proteins
Proteolytic enzymes

 
Citation counts: Google Scholar Search Google Scholar
Created: Mon, 28 Mar 2011, 14:54:32 EST by Noela Stallard on behalf of Library - Information Access Service